Nivolumab for advanced melanoma – second or third line
NIHR HSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NIHR HSC. Nivolumab for advanced melanoma – second or third line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014
NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc@contacts.bham.ac.uk